parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in enterocytes	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 355	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 16954

receipt 16963: PCK2 in dopamine neurons, braak

power: full sample -0.03 (p 0.922, n 18), 95% CI -0.49 to +0.45. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.03 (p 0.908, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.10 (p 0.690, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.12, sign flips 5; without severely affected donors -0.03 (p 0.922, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PCK2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 16962: PCK2 in microglia, braak

power: full sample +0.16 (p 0.532, n 18), 95% CI -0.33 to +0.58. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.29 (p 0.235, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.28 (p 0.254, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.26, sign flips 0; without severely affected donors +0.16 (p 0.532, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PCK2 in microglia.

case closed: nothing better to follow up.

loading the receipts